Dr. Martin Angst, MD

Anesthesiology Stanford, CA Male
NPI: 1386694529
Total Payments
$103,821
2023 Payments
$40,209
Companies
5
Transactions
22
Medicare Patients
110
Medicare Billing
$12,695

Payment Breakdown by Category

Consulting$96,105 (92.6%)
Research$7,586 (7.3%)
Food & Beverage$129.15 (0.1%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $96,105 15 92.6%
Unspecified $7,586 6 7.3%
Food and Beverage $129.15 1 0.1%

Payments by Type

General
$96,234
16 transactions
Research
$7,586
6 transactions

Top Paying Companies

Company Total Records Latest Year
Collegium Pharmaceutical, Inc. $93,660 13 $0 (2023)
Endo Pharmaceuticals Inc. $6,452 5 $0 (2022)
Persion Pharmaceuticals LLC $2,445 2 $0 (2020)
Hikma Pharmaceuticals USA $1,135 1 $0 (2019)
Grifols, S.A. $129.15 1 $0 (2021)

Payment History by Year

Year Amount Transactions Top Company
2023 $40,209 3 Collegium Pharmaceutical, Inc. ($40,209)
2022 $30,803 8 Collegium Pharmaceutical, Inc. ($25,537)
2021 $26,712 5 Collegium Pharmaceutical, Inc. ($26,583)
2020 $1,302 2 Persion Pharmaceuticals LLC ($1,207)
2019 $4,794 4 Persion Pharmaceuticals LLC ($1,238)

All Payment Transactions

22 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
06/22/2023 Collegium Pharmaceutical, Inc. Xtampza (Drug), Belbuca, Nucynta Consulting Fee Cash or cash equivalent $18,875.00 General
Category: Opioid Analgesic
06/08/2023 Collegium Pharmaceutical, Inc. Xtampza (Drug), Belbuca, Nucynta Consulting Fee Cash or cash equivalent $20,167.00 General
Category: Opioid Analgesic
02/09/2023 Collegium Pharmaceutical, Inc. Xtampza (Drug), Belbuca, Nucynta Consulting Fee Cash or cash equivalent $1,167.00 General
Category: Opioid Analgesic
05/12/2022 Collegium Pharmaceutical, Inc. Xtampza (Drug) Consulting Fee Cash or cash equivalent $4,000.00 General
Category: Opioid Analgesic
05/12/2022 Collegium Pharmaceutical, Inc. Xtampza (Drug) Consulting Fee Cash or cash equivalent $4,000.00 General
Category: Opioid Analgesic
05/12/2022 Endo Pharmaceuticals Inc. OPANA (Drug) — Cash or cash equivalent $824.80 Research
Study: ER/LA Opiod PMR 3033-11 HST F2F • Category: PAIN
05/12/2022 Endo Pharmaceuticals Inc. OPANA (Drug) — Cash or cash equivalent $824.80 Research
Study: ER/LA Opiod PMR 3033-11 HST F2F • Category: PAIN
04/14/2022 Collegium Pharmaceutical, Inc. Xtampza (Drug) Consulting Fee Cash or cash equivalent $9,332.00 General
Category: Opioid Analgesic
04/14/2022 Endo Pharmaceuticals Inc. OPANA (Drug) — Cash or cash equivalent $1,924.26 Research
Study: ER/LA Opiod PMR 3033-11 HST F2F • Category: PAIN
01/27/2022 Collegium Pharmaceutical, Inc. Xtampza (Drug) Consulting Fee Cash or cash equivalent $8,205.00 General
Category: Opioid Analgesic
01/27/2022 Endo Pharmaceuticals Inc. OPANA (Drug) — Cash or cash equivalent $1,691.87 Research
Study: ER/LA Opiod PMR 3033-11 HST F2F • Category: PAIN
12/16/2021 Collegium Pharmaceutical, Inc. — Consulting Fee Cash or cash equivalent $10,583.33 General
12/01/2021 Grifols, S.A. — Food and Beverage Cash or cash equivalent $129.15 General
07/29/2021 Collegium Pharmaceutical, Inc. — Consulting Fee Cash or cash equivalent $7,625.00 General
07/29/2021 Collegium Pharmaceutical, Inc. — Consulting Fee Cash or cash equivalent $1,375.00 General
01/27/2021 Collegium Pharmaceutical, Inc. — Consulting Fee Cash or cash equivalent $7,000.00 General
01/27/2020 Persion Pharmaceuticals LLC ZOHYDRO ER (Drug) Consulting Fee Cash or cash equivalent $1,206.76 General
Category: PAIN
01/27/2020 Collegium Pharmaceutical, Inc. — Consulting Fee Cash or cash equivalent $95.58 General
11/27/2019 Persion Pharmaceuticals LLC ZOHYDRO ER (Drug) Consulting Fee Cash or cash equivalent $1,237.97 General
Category: PAIN
11/27/2019 Collegium Pharmaceutical, Inc. — Consulting Fee Cash or cash equivalent $1,235.38 General
11/27/2019 Endo Pharmaceuticals Inc. OPANA (Drug) — Cash or cash equivalent $1,185.86 Research
Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL OF STRUCTURED OPIOID DISCONTINUATION VERSUS CONTINUED OPIOID THERAPY IN SUBOPTIMAL AND OPTIMAL RESPONDERS TO HIGH-DOSE LONG-TERM OPIOID ANALGESIC THERAPY FOR CHRONIC PAIN • Category: PAIN
11/27/2019 Hikma Pharmaceuticals USA Methadone HCL (Drug) — Cash or cash equivalent $1,134.81 Research
Study: Opioid PMR Study • Category: Psychiatry/Psychology

Research Studies & Clinical Trials

Study Name Company Amount Records
ER/LA Opiod PMR 3033-11 HST F2F Endo Pharmaceuticals Inc. $5,266 4
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL OF STRUCTURED OPIOID DISCONTINUATION VERSUS CONTINUED OPIOID THERAPY IN SUBOPTIMAL AND OPTIMAL RESPONDERS TO HIGH-DOSE LONG-TERM OPIOID ANALGESIC THERAPY FOR CHRONIC PAIN Endo Pharmaceuticals Inc. $1,186 1
Opioid PMR Study Hikma Pharmaceuticals USA $1,135 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 3 47 47 $75,594 $10,120
2022 1 23 23 $8,556 $895.26
2021 1 25 27 $10,044 $1,074
2020 1 15 15 $5,580 $605.31
Total Patients
110
Total Services
112
Medicare Billing
$12,695
Procedure Codes
6

All Medicare Procedures & Services

6 procedure records from CMS Medicare Utilization

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
00210 Anesthesia for other procedure on brain Facility 2023 12 12 $51,542 $7,057 13.7%
00520 Anesthesia for other closed procedure on chest Facility 2023 12 12 $15,495 $2,166 14.0%
36620 Insertion of artery tube for blood sampling or infusion through skin Facility 2023 23 23 $8,556 $897.69 10.5%
36620 Insertion of artery tube for blood sampling or infusion through skin Facility 2022 23 23 $8,556 $895.26 10.5%
36620 Insertion of arterial catheter for blood sampling or infusion, accessed through the skin Facility 2021 25 27 $10,044 $1,074 10.7%
36620 Insertion of arterial catheter for blood sampling or infusion, accessed through the skin Facility 2020 15 15 $5,580 $605.31 10.8%

About Dr. Martin Angst, MD

Dr. Martin Angst, MD is a Anesthesiology healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1386694529.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Martin Angst, MD has received a total of $103,821 in payments from pharmaceutical and medical device companies, with $40,209 received in 2023. These payments were reported across 22 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($96,105).

As a Medicare-enrolled provider, Angst has provided services to 110 Medicare beneficiaries, totaling 112 services with total Medicare billing of $12,695. Data is available for 4 years (2020–2023), covering 6 distinct procedure/service records.

Practice Information

  • Specialty Anesthesiology
  • Location Stanford, CA
  • Active Since 05/10/2006
  • Last Updated 04/08/2024
  • Taxonomy Code 207L00000X
  • Entity Type Individual
  • NPI Number 1386694529

Products in Payments

  • Xtampza (Drug) $65,746
  • OPANA (Drug) $6,452
  • ZOHYDRO ER (Drug) $2,445
  • Methadone HCL (Drug) $1,135

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Anesthesiology Doctors in Stanford

Lawrence Chu, Md, MD

Anesthesiology — Payments: $246,104

Anesthesiology $246,104

Hendrikus Lemmens, Md, MD

Anesthesiology — Payments: $202,103

Anesthesiology $202,103

Brendan Carvalho, Md, MD

Anesthesiology — Payments: $169,205

Anesthesiology $169,205

Vanessa Moll, M.d, M.D

Anesthesiology — Payments: $81,544

Anesthesiology $81,544

Dr. William Feaster, M.d, M.D

Anesthesiology — Payments: $68,457

Anesthesiology $68,457

Vladimir Nekhendzy, Md, MD

Anesthesiology — Payments: $64,393

Anesthesiology $64,393